This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia; reperfusion injury	Mannan-binding lectin-associated serine protease-2 (MASP-2)	Studies in mice suggest that inhibiting MASP-2 could help treat ischemia and reperfusion injury. In a mouse model of myocardial ischemia and reperfusion injury, deletion of Masp-2 lowered infarct size and tissue loss compared with those in wild-type mice. In a mouse model of gastrointestinal ischemia and reperfusion injury, deletion of Masp-2 or pretreatment with an anti-Masp-2 mAb decreased tissue damage compared with no treatment or treatment with control antibodies. Next steps include clinical testing of a recombinant MASP-2 human antibody in collaboration with Omeros Corp.	Patent applications filed; licensed to Omeros	Schwaeble, W.J. *et al. Proc. Natl. Acad. Sci. USA*; published online April 18, 2011; doi:10.1073/pnas.1101748108 **Contact:** Wilhelm J. Schwaeble, University of Leicester, Leicester, U.K. e-mail: ws5@le.ac.uk

SciBX 4(18); doi:10.1038/scibx.2011.513
Published online May 5, 2011